Kim Dae Hun, Jeong Nam Ji, Im Myung, Lee Young, Seo Young Joon, Lee Jeung Hoon
Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea.
Ann Dermatol. 2013 May;25(2):229-31. doi: 10.5021/ad.2013.25.2.229. Epub 2013 May 10.
Trastuzumab (Herceptin), a humanized monoclonal antibody, is a cancer drug developed to target the human epidermal receptor (HER) 2, which is overexpressed in some cancer cells. Cutaneous side effects, such as folliculitis, xerosis, and alopecia have not been reported with therapies targeting HER2, in spite of the frequent observances of such with the therapies targeting the epidermal growth factor receptor. We experienced a patient in whom psoriasis was triggered by the trastuzumab treatment for breast cancer. She was a 57-year-old woman with erythematous and scaly plaques occurring a few months after starting trastuzumab, with repeated aggravation after the re-administration of trastuzumab for the breast cancer. Histologic examination showed the typical features of psoriasis with parakeratosis, epidermal hyperplasia, elongation of the rete ridges, and a lymphocytic and polymorphonuclear cell infiltrate in the dermis. To the best of our knowledge, this is the first report of psoriasis triggered by trastuzumab treatment for breast cancer.
曲妥珠单抗（赫赛汀）是一种人源化单克隆抗体，是一种针对人类表皮受体（HER）2开发的抗癌药物，HER2在某些癌细胞中过度表达。尽管针对表皮生长因子受体的治疗经常出现诸如毛囊炎、皮肤干燥和脱发等皮肤副作用，但针对HER2的治疗尚未有此类报告。我们遇到一名患者，其乳腺癌的曲妥珠单抗治疗引发了银屑病。她是一名57岁女性，在开始使用曲妥珠单抗几个月后出现红斑鳞屑斑块，在乳腺癌再次使用曲妥珠单抗后病情反复加重。组织学检查显示银屑病的典型特征，包括角化不全、表皮增生、 rete嵴延长以及真皮层淋巴细胞和多形核细胞浸润。据我们所知，这是曲妥珠单抗治疗乳腺癌引发银屑病的首例报告。
